Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective, Observational study to compare the clinical outcomes and health care costs between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with non-valvular atrial fibrillation

Trial Profile

A Retrospective, Observational study to compare the clinical outcomes and health care costs between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with non-valvular atrial fibrillation

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation; Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARISTOPHANES
  • Most Recent Events

    • 14 Sep 2018 New trial record
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
    • 29 Aug 2018 Results comparing clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients (n=162,707) presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top